Investigating the Presence of Falsified and Poor-Quality Fixed-Dose Combination Artemether-Lumefantrine Pharmaceutical Dosage Forms in Kumasi, Ghana

Table 3

Results of analyses of market samples using the developed RP-HPLC method.

Formulation	Sample code	Retention time L/A (min)	Percentage content of artemether (%)  SD	^ΨPercentage content of lumefantrine (%)	Remarks on API content
Tablet	LZT	1.44/5.38	97.76  1.03	91.81  1.14	Passed
	LNT	1.41/5.38	99.68  0.89	97.55 ± 1.05	Passed
	MLT	1.39/5.36	99.50  0.23	98.33  1.23	Passed
	LFT	1.40/5.38	99.49  0.18	96.83  0.28	Passed
	CTT	1.41/5.37	99.89  0.76	99.12  0.97	Passed
	TMT	1.39/5.38	96.90  0.25	91.64  1.11	Passed
	IDT	1.40/5.38	94.94  0.06	92.16  1.26	Passed
	DMT	1.39/5.38	99.68  0.34	96.52  0.73	Passed
Suspension	MLS	1.42/5.30	98.37  0.54	99.71  0.27	Passed
	LFS	1.42/5.40	99.92  0.32	97.98  1.09	Passed
	IDS	1.42/5.40	100.10  0.25	91.27  1.16	Passed
	LNS	1.42/5.43	98.50  0.88	97.72  1.02	Passed
	STS	1.42/5.42	116.76  0.94	80.35  1.01	Failed
	BMS	1.42/5.43	88.31  0.44	82.08  0.98	Failed

L = lumefantrine. A = artemether. Acceptance criteria (BP): 90%–110%. ^ΨAcceptance criteria (BP): 90%–110%.